Aptevo Therapeutics (APVO) News Today → No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free (From Hedgeye) (Ad) Free APVO Stock Alerts $0.83 +0.04 (+5.06%) (As of 06/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 8, 2024 | investorplace.comAPVO Stock Earnings: Aptevo Therapeutics Beats EPS for Q1 2024May 2, 2024 | msn.comWhy Aspen Aerogels Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving PremarketApril 11, 2024 | msn.comWhy Aptevo Therapeutics Stock Is CrateringApril 11, 2024 | investorplace.comWhy Is Aptevo Therapeutics (APVO) Stock Down 56% Today?March 7, 2024 | marketwatch.comAptevo Therapeutics Up 20% on Positive Interim Data for Tumor DrugMarch 7, 2024 | finance.yahoo.comAlligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4March 7, 2024 | marketbeat.comTrading was temporarily halted for "APVO" at 11:03 AM with a stated reason of "LULD pause."March 7, 2024 | marketbeat.comTrading was temporarily halted for "APVO" at 10:03 AM with a stated reason of "LULD pause." Trading set to resume at 11:03 AM. March 7, 2024 | marketbeat.comTrading was temporarily halted for "APVO" at 11:03 AM with a stated reason of "LULD pause."March 7, 2024 | marketbeat.comTrading was temporarily halted for "APVO" at 10:03 AM with a stated reason of "LULD pause."March 7, 2024 | marketbeat.comTrading was temporarily halted for "APVO" at 09:03 AM with a stated reason of "LULD pause."March 6, 2024 | ca.finance.yahoo.comAptevo Therapeutics Inc (AP8N.BE)March 6, 2024 | investing.comAptevo Therapeutics enacts reverse stock split to meet Nasdaq requirementsMarch 6, 2024 | marketbeat.comTrading was temporarily halted for "APVO" at 07:03 PM with a stated reason of "News pending."March 5, 2024 | investorplace.comAPVO Stock Earnings: Aptevo Therapeutics Beats EPS for Q4 2023March 5, 2024 | finance.yahoo.comAptevo Therapeutics Inc (AP8N.DU)March 4, 2024 | msn.comAptevo Therapeutics down 13%, will effect 1-for-44 reverse stock splitMarch 1, 2024 | uk.finance.yahoo.comPD-1 and PD-L1 Inhibitors Competitive Landscape Report 2024: Clinical Assessment of Over 200 Drugs Being Developed by More than 180 CompaniesFebruary 9, 2024 | investing.comAptevo Therapeutics Inc (APVO)February 7, 2024 | msn.comAptevo Therapeutics Stockholders Approve Reverse SplitJanuary 24, 2024 | finance.yahoo.comAptevo Therapeutics Inc. (APVO)November 22, 2023 | msn.comAptevo Therapeutics files to sell up to 32.03M shares of common stock for holdersNovember 14, 2023 | msn.comAptevo Therapeutics GAAP EPS of -$0.50November 14, 2023 | finance.yahoo.comAptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business UpdateNovember 1, 2023 | finanznachrichten.deAptevo Therapeutics: Aptevo to Present at Bio-Europe ConferenceNovember 1, 2023 | finance.yahoo.comAptevo to Present at Bio-Europe ConferenceOctober 21, 2023 | thestreet.comWith New Cash Aptevo Goes It Alone on Prostate Drug, Shares Up - Biotech MoversSeptember 26, 2023 | money.usnews.comAptevo Therapeutics IncAugust 10, 2023 | finance.yahoo.comAptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business UpdateAugust 4, 2023 | finance.yahoo.comAptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public OfferingAugust 3, 2023 | msn.comAptevo Therapeutics (APVO) Price Target Increased by 24.14% to 18.36August 2, 2023 | benzinga.comWhy Aptevo Therapeutics Stock Is Getting ObliteratedAugust 2, 2023 | investorplace.comWhy Is Aptevo Therapeutics (APVO) Stock Down 33% Today?August 2, 2023 | msn.comAptevo Therapeutics down 25% after pricing $5M offeringAugust 2, 2023 | finance.yahoo.comAptevo Therapeutics Inc. Announces Pricing of $5 Million Public OfferingJuly 18, 2023 | finanznachrichten.deAptevo Therapeutics: Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AMLJuly 18, 2023 | benzinga.comAptevo Therapeutics Stock Is Sinking Today - Here's WhyJune 29, 2023 | ca.finance.yahoo.comAPVO - Aptevo Therapeutics Inc.May 11, 2023 | finance.yahoo.comAptevo Therapeutics Reports 1Q23 Financial Results and Provides Business UpdateApril 1, 2023 | finance.yahoo.comAptevo Therapeutics Full Year 2022 Earnings: EPS Beats ExpectationsMarch 30, 2023 | finance.yahoo.comAptevo Therapeutics Raises $9.6 Million in Non-Dilutive FundingMarch 30, 2023 | finance.yahoo.comAptevo Therapeutics Reports 2022 Financial Results and Provides Business UpdateJanuary 9, 2023 | finance.yahoo.comAptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid TumorsDecember 20, 2022 | finance.yahoo.comAptevo Stock Jumps As Acute Myeloid Leukemia Combo Therapy Achieves 100% Clinical Benefit RateDecember 14, 2022 | benzinga.comShort Volatility Alert: Aptevo TherapeuticDecember 12, 2022 | finance.yahoo.com100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)November 10, 2022 | finance.yahoo.comAptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business HighlightsNovember 9, 2022 | finance.yahoo.comAlligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer TherapeuticsNovember 3, 2022 | finance.yahoo.comAptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and ExpositionOctober 1, 2022 | seekingalpha.comAPVO Aptevo Therapeutics Inc. Get Aptevo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter. Email Address Nvidia needs this one obscure firm (Ad)In my new investigation, I detail why this is the single most important factor in the future of AI. I explain what this Keystone technology is… why it’s so critical to the future of not just AI but mankind… You must read this new presentation from Porter Stansberry. APVO Media Mentions By Week APVO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APVO News Sentiment▼0.000.75▲Average Medical News Sentiment APVO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APVO Articles This Week▼00▲APVO Articles Average Week Get Aptevo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: KPRX News ELAB News IMNN News KTRA News GHSI News MIRA News VCNX News AVTX News HUGE News ERNA News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APVO) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored